Ursula Linne-Mclaren briefly discusses valuable guidance for patients and caregivers, particularly those considering bispecific therapies, providing a supportive perspective on the journey through R/R MM treatment.
Maintenance Teclistamab Yields Preliminary Activity in NDMM
All evaluable patients achieved minimal residual disease negativity following teclistamab-based treatment in the phase 3 MajesTEC-4/EMN30 trial.
Mitigating AEs and Protecting QOL Following Talquetamab in Multiple Myeloma
Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.
D-VRd Regimen Sustains MRD Response In Newly Diagnosed Multiple Myeloma Subgroup
Daratumumab plus VRd showed a deepened MRD and PFS rate for patients with transplant-ineligible or -deferred newly diagnosed multiple myeloma.
Exploring the Potential Role of JAK Inhibitors in Multiple Myeloma
James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.
Multiple Myeloma Experts Face Off on Sequencing Therapy Options
Experts in multiple myeloma gathered to debate current treatment options in the space during a recent Face Off.
Optimal Sequencing Between CAR T and Bispecifics in Multiple Myeloma
The use of CAR T-cell therapy and other sequencing options were discussed for patients with multiple myeloma.